Crossmark

Bedside-available strategies to minimise P-SILI and VILI during ARDS

Published Online: 2024-03-18

Published Print: 2024-04

Authors

Roca, Oriol https://orcid.org/0000-0003-3841-4551
Telias, Irene

Grieco, Domenico L.
License Information

Text and Data Mining valid from 2024-03-18

Version of Record valid from 2024-03-18
More Information

Article History

Received: 11 December 2023

Accepted: 17 February 2024

First Online: 18 March 2024

Declarations

:

: OR reports receiving a research grant from Hamilton Medical AG and Fihser&Paykel Healthcare Ltd, speaker fees from Hamilton Medical AG, Fisher&Paykel Healthcare Ltd, Aerogen Ltd, and non-financial research support from Timpel, and he is a minority stakeholder of Tesai Care SL, all outside the submitted work. DLG has received speaking fees from Gilead, Intersurgical, MSD and GE, and reports having received travel accommodation from Fisher and Paykel. DLG discloses a research grant from GE. IT receives salary support grant from the Canadian Institutes for Health Research in the form of a Post-Doctoral Fellowship Award, teaching honoraria from Medtronic, Getinge, and consulting fees from MbMED SA, all outside the submitted work.

Document is current